Paper Details

  1. Home
  2. Paper Details

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Author: DiNardoCourtney D, DöhnerHartmut, EsteveJordi, FenauxPierre, GarciaJacqueline S, HavelangeViolaine, HongWan-Jen, HájekRoman, IllésÁrpád, JangJun-Ho, JonasBrian A, KollerElizabeth, KonoplevaMarina, LavieDavid, LeberBrian, LemoliRoberto M, LetaiAnthony, PejsaVlatko, PorkkaKimmo, PotluriJalaja, PratzKeith W, PullarkatVinod, ThirmanMichael J, TurgutMehmet, WangJianxiang, WeiAndrew H, YamamotoKazuhito, YehSu-Peng, YoonSung-Soo, ZhouYing

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that in previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone. The incidence of febrile neutropenia was higher in the venetoclax-azacitidine group than in the control group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study. METHODS: We randomly assigned previously untreated patients with confirmed AM...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2012971

データ提供：米国国立医学図書館（NLM）

Combining Azacitidine and Venetoclax for Previously Untreated Acute Myeloid Leukemia

This study explores a novel approach to treating acute myeloid leukemia (AML), a serious blood cancer. AML is characterized by the rapid growth of abnormal white blood cells, which can crowd out healthy blood cells. The researchers aimed to investigate the efficacy and safety of combining azacitidine, a hypomethylating agent, with venetoclax, a BCL-2 inhibitor, in patients with previously untreated AML who were ineligible for standard induction therapy.

The study found that the combination of azacitidine and venetoclax led to a significant improvement in overall survival compared to azacitidine alone. The combination also resulted in a higher incidence of complete remission. However, the study also noted a higher incidence of febrile neutropenia, a potentially serious side effect. The researchers concluded that the combination of azacitidine and venetoclax is a promising treatment option for patients with previously untreated AML who are ineligible for standard induction therapy.

A New Hope for AML Treatment: A Collaborative Approach

This study highlights the potential of combining different medications to improve the treatment of AML. The combination of azacitidine and venetoclax showed significant benefits in terms of overall survival and remission rates. However, it's crucial to carefully monitor patients receiving this combination therapy to manage potential side effects, particularly febrile neutropenia.

Navigating the Complexities of Cancer Treatment: A Journey of Shared Decision-Making

This study underscores the importance of shared decision-making in cancer treatment. Patients should have a clear understanding of the potential benefits and risks of their medications and be actively involved in their treatment plan. Open communication with healthcare providers is crucial for navigating the complex world of cancer treatment and ensuring the best possible outcomes.

Dr. Camel's Conclusion

This study offers a beacon of hope in the ongoing fight against AML. The combination of azacitidine and venetoclax represents a promising step forward in developing more effective and personalized treatment options for this challenging disease. Just as a traveler in the desert seeks out oases for survival, cancer patients rely on innovative therapies to navigate the complexities of their illness. This research brings us closer to finding new oases in the desert of cancer treatment, offering hope and improved outcomes for patients.

Date :
  1. Date Completed 2020-08-25
  2. Date Revised 2023-03-25
Further Info :

Pubmed ID

32786187

DOI: Digital Object Identifier

10.1056/NEJMoa2012971

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.